Transferrin receptor 2 (Tfr2) genetic deletion makes transfusion-independent a murine model of transfusion-dependent β-thalassemia

Simona Maria Di Modica | Emanuele Tanzi | Violante Olivari
Maria Rosa Lidonnici | Mariateresa Pettinato | Alessia Pagani
Francesca Tiboni | Valeria Furiosi | Laura Silvestri | Giuliana Ferrari
Stefano Rivella | Antonella Nai

1Regulation of Iron Metabolism Unit, Division of Genetics and Cell Biology, Ospedale San Raffaele, Milan, Italy
2Vita Salute San Raffaele University, Milan, Italy
3San Raffaele Telethon Institute for Gene Therapy (SR-TIGET), Ospedale San Raffaele, Milan, Italy
4Division of Hematology, Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA

Abstract
β-thalassemia is a genetic disorder caused by mutations in the β-globin gene, and characterized by anemia, ineffective erythropoiesis and iron overload. Patients affected by the most severe transfusion-dependent form of the disease (TDT) require lifelong blood transfusions and iron chelation therapy, a symptomatic treatment associated with several complications. Other therapeutic opportunities are available, but none is fully effective and/or applicable to all patients, calling for the identification of novel strategies. Transferrin receptor 2 (TFR2) balances red blood cells production according to iron availability, being an activator of the iron-regulatory hormone hepcidin in the liver and a modulator of erythropoietin signaling in erythroid cells. Selective Tfr2 deletion in the BM improves anemia and iron-overload in non-TDT mice, both as a monotherapy and, even more strikingly, in combination with iron-restricting approaches. However, whether Tfr2 targeting might represent a therapeutic option for TDT has never been investigated so far. Here, we prove that BM Tfr2 deletion is sufficient to avoid long-term blood transfusions required for survival of Hbbth1/th2 animals, preventing mortality due to chronic anemia and reducing transfusion-associated complications, such as progressive iron-loading. Altogether, TFR2 targeting might represent a promising therapeutic option also for TDT.
1 | INTRODUCTION

β-thalassemia is an autosomal recessive disorder due to mutations in the β-globin gene or in its promoter, that result in reduced or absent β-globin chain synthesis. The unbalance between α- and β-globin chains determines the accumulation of unstable and insoluble α-globin/heme complexes, called hemichromes, that precipitate, generate cytotoxic reactive oxygen species and lead to endoplasmic reticulum stress.1–3 All these features affect the maturation and viability of erythroid precursors, resulting in ineffective erythropoiesis (IE), a tentative compensatory expansion of extramedullary erythropoiesis, that leads to anemia, splenomegaly, and decreased red blood cells (RBC) survival.3

The augmented proliferation of early erythroid precursors increases the production of the erythroid regulator erythrophereone (ERFE), a peptide hormone released in the circulation to inhibit the transcription of the iron-regulatory hormone hepcidin.4,5 Suppression of hepcidin increases intestinal iron absorption and release from macrophages, resulting in progressive iron-loading, one of the most relevant complications in β-thalassemia.6–8 Of note, increased iron uptake by erythroid cells further contributes to IE, enhancing heme and hemicrhome production.9–11

Anemia severity can range from mild to severe and patients are classified as Non-Transfusion Dependent (NTDT) or Transfusion Dependent (TDT) based on their blood transfusion requirement.12 Patients affected by severe TDT require lifelong blood transfusions and iron chelation to control iron-overload, symptomatic treatments that affect the quality of life.3,13,14 For years, the only curative option was allogeneic bone marrow (BM) transplantation, an approach effective in more than 90% of cases, but limited by the insufficient number of HLA-matched donors and, in some cases, associated to severe post-transplant complications.15–17 Two promising innovative treatments, Activin Receptor Ligand Trap Luspatercept-Reblozyl18,19 and the gene therapy product Zynaptiyo20–22 received FDA and EMA approval and EMA conditional marketing authorization for TDT patients, respectively; however, these are not fully effective in all patients and/or suitable for selected individuals.24 For these reasons, the identification of novel therapeutic approaches, to be eventually combined with available therapies, is a clinical need.

Transferrin receptor 2 (TFR2), the hemochromatosis type III gene,25 sensing the iron bound transferrin,26 transcriptionally activates hepcidin in the liver.27–29 The partially unknown mechanism involves the modulation of the Bone Morphogenetic Protein-Son of Mother Against Decapentaplegic (BMP-SMAD) signaling pathway.30–34 TFR2 is a sensor of circulating iron also in erythroid cells, where it binds Erythropoietin (EPO) receptor (EPOR)35 and inhibits the activation of the EPO-EPOR signaling.36 Indeed, wild-type mice lacking BM Tfr2 show enhanced erythropoiesis and increased RBC count, without changes in EPO levels.36 Thus, TFR2 balances RBC production with systemic iron homeostasis, according to circulating iron levels. When transferrin saturation (TS) increases, it is stabilized on the plasma membrane of both hepatocytes, activating hepcidin to limit plasma iron flux,37,38 and erythroblasts39 preventing excessive erythropoietic expansion. When TS decreases, TFR2 is shed from the plasma membrane39 and/or degraded in lysosomes40 enhancing both iron absorption and erythropoiesis to avoid anemia. However, the mechanism/s of the TFR2-mediated modulation of physiologic and ineffective erythropoiesis is still partially unknown and a current matter of investigation.

This function of TFR2 can be exploited for therapeutic purposes. Indeed, BM Tfr2 deletion ameliorates anemia and ineffective erythropoiesis, and partially prevents hepatic iron loading in the NTDT Hbbth1/th2 mouse model.41 This effect can be enhanced through the simultaneous downregulation of the hepcidin inhibitor Tmprss6,42,43 approach that improves the thalassemic phenotype inducing iron-restriction.44,45

Here, we aim at investigating whether TFR2 might represent a candidate therapeutic target not only for NTDT, but also for TDT, the form of the disease that requires regular blood transfusion treatment. We demonstrate that deletion of a single or both Tfr2 allele in the BM of the Hbbth1/th2 TDT murine model46 ameliorates anemia and IE, partially preventing the age-dependent iron-loading, and completely abolishing blood transfusion requirement for survival.

2 | METHODS

2.1 | Animal models

Hbbth1/+ (C57BL/6J background) and Hbbth1/– mice (C57BL/6J background) were from the Jackson Laboratories, while Tfr2–/– mice (129S2 background) were as previously described.49 Both Hbbth1/+ and Hbbth1/– mice were crossed with Tfr2–/– mice obtaining Tfr2–/–/Hbbth1/+ and Tfr2–/–/Hbbth1/– progenies on a mixed C57/129S2 background. Tfr2–/–/Hbbth1/+ and Tfr2–/–/Hbbth1/– mice were then crossbred and dated, to isolate day E14.5 embryos for fetal liver cells recovery and transplant. All animals were maintained in the animal facility at San Raffaele Scientific Institute, fed a regular rodent diet and under 12 h:12 h light: dark cycles. All animal studies were conducted under protocols approved by the Institutional Animal Care of San Raffaele Scientific Institute in accordance with the EU guidelines.

2.2 | Fetal liver transplantation and experimental design

Fetal liver cells (FLCs) isolated from day E14.5 C57/129S2 Tfr2+/–/Hbbth1/– and Tfr2–/–/Hbbth1/– embryos were used for transplantation (FLT), as described.46 In brief, 2 × 10⁶ FLCs from Tfr2–/–/Hbbth1/– and Tfr2–/–/Hbbth1/– embryos (expressing the CD45.2 surface antigen) were transplanted into lethally irradiated C57BL/6-Ly-5.1 male mice (expressing the CD45.1 surface antigen), generating Hbbth1/– mice with both (Tfr2BMWT/Hbbth1/–) and a single (Tfr2BMWT/Hbbth1/–) or no (Tfr2BMWT/Hbbth1/–) Tfr2 allele in the BM.
A cohort of mice was sacrificed eight weeks after FLT for phenotypic characterization, while a second cohort was maintained longer for the evaluation of blood transfusion requirement. Blood was collected by tail vein puncture for complete blood count (CBC) every four weeks, and weekly for monitoring hemoglobin (Hb) levels until 30 weeks after FLT, when mice were sacrificed. A blood transfusion was performed when Hb decreased to $\leq 5.5$ g/dL. At sacrifice, blood was collected for CBC and serum iron, EPO and ERFE measurement; liver, spleen, kidneys and heart were weighed, dissected and snap-frozen immediately for RNA analysis, or dried for tissue iron quantification or processed for FACS analysis. BM cells were harvested and processed for flow cytometry or RNA analysis.

2.3 | Hematological analysis

CBC and reticulocytes percentage were determined on a IDEXX Procyte dx automated blood cell analyzer (Idexx Laboratories).

For Hb evaluation, a single drop of blood was collected and analyzed using the Hemoglobin colorimetric micro assay kit (Alpha Diagnostic International), following manufacturer’s recommendations. Blood smears were stained with Giemsa or Crystal Violet solution and pictures were captured using a Leica DM5000 microscope equipped with a Leica DFC480 digital camera.

Serum iron and total iron binding capacity (TIBC) were determined using The Total Iron Binding Capacity Kit (Randox Laboratories Ltd.), according to the manufacturer’s instructions. Transferrin saturation was calculated as the ratio between serum iron and TIBC.

Serum EPO and ERFE levels were measured using mouse EPO quantikine set (R&D System) and Intrinsic Mouse Erythroferrone ELISA kit (Intrinsic Lifesciences) respectively, following standard protocol.

2.4 | Blood transfusions

Mice were transfused with $300 \mu l$ of freshly harvested blood from wild-type C57BL/6J male mice via retro-orbital injection, as previously described. The last transfusion was performed two weeks before sacrifice.

2.5 | Tissue iron content

Tissue samples, dried at $65^\circ C$ for 1 week, were weighed and digested in acid solution (3 M HCl, 0.6 M trichloroacetic acid) for 20 h at $65^\circ C$. Iron ammonium sulfate was dissolved in acid solution to generate a standard curve. The acid extracts were added to working chromogen reagent (1 volume of 0.1% bathophenanthroline sulfate and 1% thioglycolic acid solution, 5 volumes of water, and 5 volumes of saturated sodium acetate) and incubated for 30 min at room temperature. Then, the absorbance at 535 nm was determined for the quantification of iron content.

2.6 | Flow cytometry

BM and spleen cells were pre-treated with rat-anti-mouse CD16/CD32 (BD Pharmingen) in order to block unspecific Ig binding. Cells were subsequently incubated for 30 min in the dark at $4^\circ C$ with FITC rat anti-mouse Ter119 and APC rat anti-mouse CD44 (BD Biosciences) for the evaluation of erythroid differentiation, or with FITC-conjugated anti-mouse CD45.1 and APC-conjugated anti-mouse CD45.2 antibodies (BD Biosciences) to monitor donor/host chimerism.

Analyses were performed using the FACS Canto™ II (BD Biosciences).

2.7 | Quantitative RT-PCR

RNA was extracted using the guanidinium thiocyanate-phenol-chloroform method (Trifast Reagent, Euroclone) following the standard protocol for snap-frozen liver, spleen and kidney samples. Fresh BM cells were lysed in Trifast reagent and then RNA was extracted combining the Trifast protocol followed by a resin-based purification (ReliaPrep RNA Miniprep system, Promega), after the addition of isopropanol.

cDNA was synthesized using the High-Capacity cDNA Reverse Transcription kit (Applied Biosystems), according to manufacturer’s instructions. Real-time PCR analyses were performed on 7900HT Fast Real-Time PCR System (Applied Biosystems) using specific murine TaqMan Assays-on-Demand and Master Mix (Applied Biosystems) or specific murine oligos (designed using the NCBI Pick Primer software and generated by Merck) and SYBRgreen Master Mix (Applied Biosystems). RNA levels were normalized to the expression of the housekeeping gene Ribosomal Protein L13 (Rpl13) or $\beta$-Actin (Actb). Primers used are described in Table S1 and S2.

2.8 | Statistics

Data are presented as mean ± SE. Unpaired 2-tailed Student’s t-test for multiple comparison or one-way ANOVA analysis was performed using GraphPad Prism 7.0 (GraphPad). $p < 0.05$ was considered statistically significant.

3 | RESULTS

3.1 | BM Tfr2 deletion ameliorates anemia in the Hbbth1/th2 model of transfusion-dependent $\beta$-thalassemia

As we shown previously, myeloablated wild-type (WT) animals transplanted with FLCs from Hbbth1/th2 embryos develop a severe anemia (Figure 1A), requiring blood transfusion for survival. To evaluate the effect of Tfr2 deletion on the phenotype of these animals, we engrafted FLCs from Hbbth1/th2 embryos carrying deletion of both
(Tfr2BMKO/Hbbth1/th2) or a single Tfr2 allele (Tfr2BMHet/Hbbth1/th2) into myeloablated WT animals. As controls, we used mice transplanted with FLCs from Hbbth1/th2 embryos harboring both Tfr2 alleles (Tfr2BMWT/Hbbth1/th2).

A cohort of mice was sacrificed and analyzed eight weeks after FLT, before the onset of blood transfusion requirement, for a complete phenotypic characterization. At this time-point, mice of the three genotypes were phenotypically indistinguishable with comparable body weight (Figure S1A). Chimerism was >95% and >85% in the BM and in the spleen (Figure S1B,C), respectively, in all animals. The expression of Tfr2 was reduced in agreement with the genotype of the transplanted FLCs in both organs (Figure S1D,E).

|                    | Tfr2BMWT/Hbbth1/th2 | Tfr2BMHet/Hbbth1/th2 | Tfr2BMKO/Hbbth1/th2 |
|-------------------|----------------------|-----------------------|----------------------|
| RBC (*10⁶/μl)     | 6.53±0.10            | 7.44±0.13***          | 8.57±0.17****       |
| Hb (g/dL)         | 7.69±0.11            | 8.65±0.18const        | 9.61±0.19***         |
| Hct (%)           | 29.56±0.37           | 32.39±0.54***         | 36.07±0.67***       |
| MCV (fL)          | 45.28±0.27           | 43.55±0.30**          | 42.14±0.31***       |
| MCH (pg)          | 11.77±0.06           | 11.62±0.13            | 11.21±0.04**        |
| Retics (%)        | 70.92±0.90           | 64.28±2.85*           | 60.00±1.83**        |
| PLT (*10⁶/μl)     | 1211.0±52.9          | 1264.8±43.8           | 1180.3±61.4         |
| WBC (*10⁶/μl)     | 56.72±4.03           | 67.36±6.182           | 41.42±4.44**        |

**FIGURE 1** Legend on next page.
In agreement, and in line with increased Hb, kidney Epo mRNA levels (Figure 2A) and serum EPO levels (Figure 2B) were lower in Tfr2BMKO/Hbbth1/th2 mice as compared to controls, with Tfr2 haploinsufficient Hbbth1/th2 animals showing intermediate serum EPO levels. EPO reduction, together with decreased immature erythroid precursors, limited the production of the erythroid regulator Erythroiderone (Erf) in the BM (Figure 2C), but not in the spleen (Figure 2D) with a net decrease in circulating levels (Figure 2E) in Tfr2 deficient animals, in agreement with the increased hepatic Hamp expression.

The expression levels of other EPO-EPOR target genes as B-cell lymphoma-extra large, Bcl-xl, Figure S2A,B and Epor itself (Figure S2C,D) were similar in animals of the 3 genotypes both in the BM and in the spleen. However, Erf, Bcl-xl and Epor levels relative to serum EPO were higher in Tfr2BMKO/Hbbth1/th2 than in controls both in the BM (Figure 2F–H) and in the spleen (Figure 2I–K), confirming that Tfr2 deletion boosts EPO sensitivity also in this severe model, as shown previously.

3.3 | BM Tfr2 deletion reduces α-globin transcription and unfolded protein response in erythroid tissues of Hbbth1/th2 mice

Irrespective of the Tfr2 genotype, the Hbbth1/th2 model had very low expression of the β-major globin allele relative to wt (Figure S2E), accompanied by a tentative compensatory increase in the expression of the β-minor allele (Figure S2F), in line with previous results. The mRNA levels of α-globin were high in Tfr2BMWT/Hbbth1/th2 animals relative to wt (Figure 3A), to likely counteract the low hemoglobin, but finally worsening the unbalance between α and β-globin chains, the key driver of IE in β-thalassemia.

The accumulation of free α-globin chains can be counteracted by decreasing α-globin or increasing the expression of γ-globin and the production of fetal hemoglobin. We demonstrated that BM Tfr2 deletion was associated with reduced mRNA levels of γ-globin, both as absolute value (Figure 3A), and as a ratio over the expression of the α-hemoglobin stabilizing protein (Ahsps, Figure S2G), a chaperone required to prevent the harmful aggregation of α-globin. This

**Figure 1** Bone marrow Tfr2 deletion ameliorates anemia, red blood cells morphology and ineffective erythropoiesis of transfusion-dependent Hbbth1/th2 mice. Hbbth1/th2 mice with inactivation of both Tfr2BMKO/Hbbth1/th2 or a single Tfr2BMWT/Hbbth1/th2 Tfr2 allele in the bone marrow were generated through fetal liver cells transplantation (FLT). Complete blood count [red blood cell (RBC) count, hemoglobin (Hb) levels, hematocrit (Hct), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), reticulocytes (Retic), platelet (PLT) and white blood cell (WBC) count] was evaluated 8 weeks after FLT showing anemia improvement upon Tfr2 loss [(A), mean values of 12/14 animals/genotype ± standard errors]. A cohort of Tfr2BMWT/Hbbth1/th2, Tfr2BMWT/Hbbth1/th2 and Tfr2BMKO/Hbbth1/th2 mice was sacrificed at this time point for a full phenotypic characterization. Tfr2 deletion in the bone marrow (BM); (B) ameliorated RBCs morphology (representative pictures of giemsa staining of blood smears, original magnification 100X); (C) did not correct splenomegaly (spleen size related to body weight); (D) improved erythroid differentiation [percentage of Ter119+ cells on total alive cells and subpopulation composition. Gated Clusters: proerythroblasts (I), basophilic erythroblasts (II), polychromatic erythroblasts (III), orthochromatic erythroblasts and immature reticulocytes (IV), and mature red cells (V)] both in the BM and in the spleen (SP); (E) reduced Transferrin saturation (TS); (F) did not modify liver iron content (LIC); (G) increased hepcidin (Hamp) levels relative to hepatic iron-loading [ratio between hepatic Hamp mRNA levels relative to Ribosomal protein 13 (Rpl13) and LIC]. Bars represent standard error (SE). Asterisks refer to statistically significant differences versus Tfr2BMKO/Hbbth1/th2 mice (A), (D) or as indicated. *p < 0.05; **p < 0.005; ***p < 0.001; ****p < 0.0001. Hashtags refer to statistically significant differences versus Tfr2BMWT/Hbbth1/th2 mice (A), #p < 0.005; ##p < 0.001; ###p < 0.0001.
Bone marrow Tfr2 deletion enhances erythropoietin sensitivity in erythroid tissues of Hbb<sup>th1/th2</sup> mice. Eight weeks after fetal liver transplantation erythropoietin (Epo) levels were reduced in Tfr<sup>2BMKO/Hbb<sup>th1/th2</sup></sup> mice both in the kidney (A) and in the serum (B), decreasing erythroferrone (Erfe) in the bone marrow (BM) and in the serum, but not in the spleen (C)–(E). The transcription of EPO target genes normalized on circulating EPO levels was enhanced both in the BM and in the spleen of Tfr<sup>2BMKO/Hbb<sup>th1/th2</sup></sup> mice. In the figure are reported: kidney mRNA levels of Epo relative to β-Actin (Actb) (A); serum EPO levels (B); Erfe mRNA levels of relative to Ribosomal Protein L13 (Rpl13) in the bone marrow (BM, (C)) and in the spleen (D); serum ERFE levels (E); the ratio between BM mRNA levels of Erfe, B-cell lymphoma-extra large (Bcl-xL) and Erythropoietin receptor (Epor) relative to Ribosomal Protein L13 (Rpl13) and EPO both in the BM (F),(G),(H) and in the spleen (I),(J),(K). Bars represent standard error (SE). Asterisks refer to statistically significant differences. *p < 0.05; **p < 0.005; ****p < 0.0001. [Color figure can be viewed at wileyonlinelibrary.com]
FIGURE 3  Legend on next page.
suggests that, in the absence of Tfr2, α-globin was less produced and less toxic, because of the more appropriate levels of Ahsp, pointing to a restored unbalance between α and β-globin chains. In agreement, the ratio between α and β-minor globin chains was lower in Tfr2BMKO/Hbbth1/th2 animals as compared to Tfr2BMWT/Hbbth1/th2 controls (Figure 3B).

This could be explained by an in vivo selection of erythroid cells with less unbalanced synthesis of the globin chains or, more intriguingly, by a direct inhibitory effect on α-globin transcription mediated by Tfr2 deficiency. Interestingly, the mRNA levels of the transcription factor Kruppel Like Factor 4 (Klf4), key player in the induction of α-globin expression, were reduced in the BM of Tfr2BMKO/Hbbth1/th2 mice relative to controls (Figure 3C). This raised the possibility that TFR2 might directly modulate α-globin via KLF4, but the underlying mechanism remained to be clarified. We found that also the expression of the late murine embryonic globin chain εγ is reduced in the BM of Tfr2BMKO/Hbbth1/th2 mice (Figure 3D), suggesting that KLF4 may be involved also in the transcriptional control of εγ-globin, in analogy with the KLF4-mediated common modulation of α and γ-globin genes in humans.60

To analyze more in depth the changes induced by Tfr2 deficiency in thalassemic BM cells, we focused on the endoplasmic reticulum stress, a critical consequence of free α-globin and hemichrome precipitation, that we found alleviated in Tfr2BMKO/Hbbth1/th2 mice. Indeed, the expression of several genes activated by the UPR pathways was decreased. In detail, we observed a reduction in the proportion between the spliced and unspliced forms of X-box DNA Binding Protein, UPR-specific b-ZIP transcription factor (sXbp1/Xbp1, Figure 3E), due to a diminished expression of Xbp1 (Figure S2H) in the absence of changes in total Xbp1 levels (Figure S2I). Moreover, mRNA levels of Binding Immunoglobulin Protein (Bip, Figure 3F), Growth Arrest and DNA Damage-inducible protein 34 (Gadd34, Figure 3G) and Endoplasmic Reticulum Oxidoreductase 1 (Ero1, Figure 3H) were reduced in the BM of Tfr2BMKO/Hbbth1/th2 relative to Tfr2BMWT/Hbbth1/th2 and/or Tfr2BMHet/Hbbth1/th2 mice. Surprisingly, the expression of C/EBP Homologous Protein (Chop) was increased in the BM of Tfr2 deficient animals (Figure 3I). Since CHOP is an EPO-EPOR target gene, its upregulation in BM-derived cells is in agreement with the inappropriately high EPO-EPOR signaling due to Tfr2 genetic inactivation.

Overall, these findings suggest that, in the absence of Tfr2, thalassemic erythroid cells have a reduced abundance of toxic free α-globin chains. This, together with the iron-restricted phenotype of Tfr2-deficient erythroid cells, evident by low MCV and MCH (Figure 1A), results in reduced hemichromes precipitation, as shown by the drastic decrease in the presence of Heinz bodies within Tfr2BMKO/Hbbth1/th2 RBCs (Figure 3J), and in line with the improved erythrocytes morphology (Figure 1B).

### 3.4 Blood transfusion requirement is completely abolished in Hbbth1/th2 mice lacking BM Tfr2

The beneficial effect of Tfr2 deletion was maintained over time. Tfr2BMWT/Hbbth1/th2 mice became progressively more transfusion-dependent overtime, showing Hb levels of 5.5 g/dL at 14 weeks post FLT. RBC count (Figure 4A), Hb levels (Figure 4B) and Hct (Figure 4C) were maintained stable by blood transfusions in Tfr2BMWT/Hbbth1/th2 animals for the entire follow-up, while reticulocytes were progressively reduced (Figure 4D), likely due to transfusion-mediated inhibition of erthropoiesis.67,68 In line with the reduced percentage of reticulocytes, MCV decreased during the 30-week-long period (Figure 4E). Since transfusions were interrupted at 28 weeks to minimize the confounding effect of administered blood in the erythropoietic phenotype of Tfr2BMWT/Hbbth1/th2 mice, the increase in reticulocytes and MCV observed at the time of the sacrifice likely reflected recovery of endogenous erthropoiesis. MCH increased during follow-up (Figure 4F) because of the progressive substitution of thalassemic RBCs with wild-type ones.

Tfr2BMWT/Hbbth1/th2 mice maintained higher RBC count and Hct for the entire follow-up and Hb until 16 weeks, when Hb reached values of transfused Tfr2BMWT/Hbbth1/th2 animals. Tfr2BMKO/Hbbth1/th2 mice showed RBC count, Hb levels and Hct higher than Tfr2BMWT/Hbbth1/th2 and Tfr2BMHet/Hbbth1/th2 mice for the entire 30-week-long period (Figure 4A–C). Reticulocytes count was reduced in mice lacking both BM Tfr2 alleles, but not in haploinsufficient animals (Figure 4D). MCV and MCH were decreased in a comparable manner in both Tfr2BMKO/Hbbth1/th2 and Tfr2BMWT/Hbbth1/th2 mice, indicating the development of an iron-restricted erthropoiesis, as previously shown in Tfr2BMKO/Hbbth1/th2 animals.41,42 Of note, Tfr2BMWT/Hbbth1/th2 mice required transfusion of an average 107.34 ± 15.36 μL of

---

**FIGURE 3** Bone marrow Tfr2 deletion reduces the expression of α-globin and of target genes of the unfolded protein response in the bone marrow of Hbbth1/th2 mice. Eight weeks after fetal liver transplantation Tfr2BMKO/Hbbth1/th2 mice showed decreased expression of α-globin in the bone marrow (BM, (A)), which partially corrected the unbalance with β-globin (B). The expression levels of the transcription factor Kruppel like factor 4 (Klf4, (C)), of the fetal globin εγ (D) and of several genes activated by the unfolded protein response (E)–(H) were reduced, with the exception of C/EBP Homologous Protein (Chop, (I)) which was increased. Heinz bodies in red blood cells (RBC) were decreased in mice lacking BM Tfr2 (J). In the figure are represented: BM mRNA levels of α-globin (A), α- over β-minor globin (B), Klf4 (C), εγ-globin (D), spliced over unspliced X-box DNA Binding Protein, UPR-specific b-ZIP transcription factor (sXbp1/Xbp1, (E)), Binding immunoglobulin protein (Bip, (F)), Growth arrest and DNA damage-inducible protein 34 (Gadd34, (G)), Endoplasmic Reticulum Oxidoreductase 1 (Ero1, (H)) and Chop (I) relative to Ribosomal Protein L13 (Rpl13); representative pictures of Crystal Violet staining of blood smears (Original magnification 100X) and the quantification of the percentage of RBCs carrying Heinz bodies performed in 10 different fields/animal (J). Dotted red lines indicate mean values wild-type (wt) mice. Bars represent standard error (SE). Asterisks refer to statistically significant differences. *p < 0.05; **p < 0.005; ****p < 0.0001. P-values close to 0.05 were also indicated.
blood/animal/week throughout the entire follow-up, while animals with both heterozygous and homozygous BM Tfr2 deletion did never require transfusions for survival (Figure 4G).

3.5 | BM Tfr2 deletion reduces hepatic iron-loading of aged Hbb<sup>th1/th2</sup> mice

Despite the consistent anemia improvement, erythroid differentiation did not show striking differences among the three genotypes both in the BM and in the spleen (Figure S3A). This is likely due to the suppression of ineffective and expanded erythropoiesis induced by blood transfusions<sup>67,68</sup> in Tfr<sup>2BMWT/Hbb<sup>th1/th2</sup></sup> mice. However, a reduction in the proportion of polychromatophilic erythroblasts and an increase in mature RBCs can still be detected in the spleen of Tfr<sup>2BMKO/Hbb<sup>th1/th2</sup></sup> mice as compared to Tfr<sup>2BMWT/Hbb<sup>th1/th2</sup></sup> (Figure S3A), which, in line with previous findings<sup>41,42</sup> is not paralleled by splenomegaly reduction (Figure S3B).

Also, at this late time-point Epo production from the kidney was reduced in both Tfr<sup>2BMKO/Hbb<sup>th1/th2</sup></sup> and Tfr<sup>2BMHet/Hbb<sup>th1/th2</sup></sup> mice as compared to Tfr<sup>2BMWT/Hbb<sup>th1/th2</sup></sup> (Figure S3C), compatible with improved anemia.

At difference with data from mice eight weeks after FLT, at this time point, Tfr<sup>2BMKO/Hbb<sup>th1/th2</sup></sup> mice showed lower LIC (Figure 4I) and a trend toward reduced SIC (Figure S3D) when compared with both
and in a NTDT model, irrespective of blood transfusion, LIC was not higher in Tfr2\textsuperscript{BMWT}/Hbb\textsuperscript{th1/th2} as compared to Tfr2\textsuperscript{BMHet}/Hbb\textsuperscript{th1/th2} mice (Figure 4I), likely because of the mild transfusional regimen applied.

4 | DISCUSSION

The therapy of TDT patients is still suboptimal. Recent advances in the elucidation of the pathophysiological mechanisms of the disease led to the design of novel therapeutic approaches.\textsuperscript{14,49} However, none of these is fully effective in all patients, even when the genetic defect is corrected (i.e., by gene therapy), likely because different modifiers contribute to the complex phenotype of patients. For this reason, the identification of novel strategies to be eventually combined with available treatments, as occurs in hematological cancers, might offer new therapeutic perspectives.

Our recent studies identified TFR2 as a potential promising target for the treatment of NTD β-thalassemia.\textsuperscript{41,42} However, its effectiveness in the most severe, transfusion dependent form of the disease was not yet addressed. Here, we prove that, despite the severity of the genetic defect, hematopoietic Tfr2 deletion ameliorates ineffective erythropoiesis, anemia and iron-overload also in a TDT murine model. This improvement is associated to a substantial increase in transfusion-free survival of both Tfr2\textsuperscript{BMHet}/Hbb\textsuperscript{th1/th2} and Tfr2\textsuperscript{BMKO}/Hbb\textsuperscript{th1/th2} mice, which are transfusion-independent 16 weeks after the onset of blood transfusion requirement in Tfr2\textsuperscript{BMWT}/Hbb\textsuperscript{th1/th2} animals. Besides Luspatercept, this is the sole approach not correcting the genetic defect, which revealed able to reduce blood transfusion requirement in a TDT murine model. In a clinical perspective, we can speculate that our strategy might lead to a complete transfusion independence in milder patients, and to a significant decrease in blood requirement in more severe patients.

In line with our previous findings,\textsuperscript{36,41,42} BM Tfr2 deletion does not directly influence systemic iron homeostasis, indeed both tissue and circulating iron levels are comparable among animals of the three genotypes eight weeks after FLT. However, hepcidin expression is higher in Tfr2-deficient animals despite comparable LIC, likely because of the partial correction of IE and the consequent reduction of ERFE production. On a long-term, this reduces dietary iron absorption and, in association with the higher iron consumption by the more effective erythropoiesis, prevents hepatic iron-loading with aging.

Surprisingly, hepatic iron levels were comparable between untransfused Tfr2\textsuperscript{BMHet}/Hbb\textsuperscript{th1/th2} and regularly transfused Tfr2\textsuperscript{BMWT}/Hbb\textsuperscript{th1/th2} animals: this is likely due to the mild transfusion protocol utilized that provided mice with the minimal amount of blood required for maintaining Hb levels at about 6 g/dL. If a heavier or more prolonged transfusion regimen is applied, further worsening iron loading, the beneficial effect of BM Tfr2 deletion, which abolishes blood transfusion requirement, would be even more impressive.

We previously demonstrated that Tfr2 deletion enhances EPO sensitivity of erythroid cells in both wild-type mice\textsuperscript{36} and in a NTDT model,\textsuperscript{41} and here confirm that this occurs in a TDT model, too. However, this finding does not completely explain the mechanism responsible for the TFR2-mediated improvement of thalassemic erythropoiesis. In the attempt of unravel this point, we found that the BM expression of α-globin is reduced, likely through the inhibition of the transcription factor Klf4.\textsuperscript{58,59} Of note, we observed a minimal decreased expression also of ε-globin chain, excluding that Tfr2 inactivation improves erythropoiesis reactivating fetal hemoglobin. This inhibition of ε-globin transcription is unlikely to negatively impact on hemoglobin synthesis, since the strong effect on α-globin, and might occur through the downmodulation of Klf4 as for human γ-globin.\textsuperscript{60}

Low α-globin transcription and iron-restricted erythropoiesis, as indicated by low MCV and MCH in Tfr2\textsuperscript{BMKO}/Hbb\textsuperscript{th1/th2} mice, contribute to decrease hemichrome formation and precipitation,\textsuperscript{14,69} as supported by the improved RBC morphology and by reduced presence of denatured hemoglobin in Tfr2-deficient animals. This limits toxicity associated to excess α-globin and minimizes the endoplasmic reticulum stress due to unfolded protein response, as shown by a diminished expression of several UPR target genes. Surprisingly, Chop mRNA levels are even increased in the BM of Tfr2 deficient animals, claiming for a UPR-independent regulation. Since previous data suggested that EPO can directly activate Chop transcription, thus promoting hemoglobinization,\textsuperscript{70,71} and that Chop deletion in vascular smooth muscle cells activates Klf4 transcription,\textsuperscript{72} we propose that in our model Tfr2 deletion, increasing EPO signaling, activates Chop transcription, that, in turn, limits the expression of Klf4 and α-globin, partially correcting the αβ-globin chains unbalance and improving erythroid differentiation and hemoglobinization.

The missing point is the lack of a tool to pharmacologically inhibit TFR2. We tested specific antisense oligonucleotides (IONIS Pharmaceuticals), which, despite effective in erythroid cells in vitro, failed in downregulating Tfr2 expression in erythroid tissues when systemically administered in vivo (unpublished data), possibly because of poor cellular uptake.\textsuperscript{73,74} In the future, the introduction of specific modifications for erythroid targeting or encapsulation into nanoparticles/liposomes for BM delivery\textsuperscript{75,76} could represent an approach to solve this challenging issue.

Overall, our findings demonstrate that TFR2 targeting represents a new promising therapeutic opportunity for the management of β-thalassemia, able to strongly reduce blood transfusion requirement, worth to be tested both as a monotherapy and in association with available treatments.

AUTHOR CONTRIBUTIONS

Simona Maria Di Modica performed research, analyzed results and contributed to paper writing; Emanuele Tanzi, Violante Olivari, Maria Rosa Lidonnici, Mariateresa Pettinato, Alessia Pagani, Francesca Tiboni and Valeria Furiosi performed experiments; Laura Silvestri contributed to critical data analysis; Giuliana Ferrari participated to data analysis and paper editing; Stefano Rivella provided the thalassemia major murine model and edited the paper; Antonella Nai conceived the experiments, analyzed results, wrote and reviewed the manuscript. All Authors approved the final version of the manuscript.
ACKNOWLEDGMENTS
The authors are indebted to Clara Camaschella for criticism and suggestions. We thank Intrinsic Lifesciences for providing the Intrinsic Mouse Erythroferrone ELISA kit. Open access funding provided by BIBLIOSAN.

FUNDING INFORMATION
This work was supported by Cariplo Foundation (“Young Investigator” Grant no. 2017-0916), Cooley’s Anemia Foundation (Research Fellowship 2017–2019), American Society of Hematology (Global Research Award 2017 and Supplement Award 2021), European Hematology Association (Advanced Research Grant 2020) and Italian Ministry of Health (GR-2019-12369583) to A.N., by Fondazione Telethon (Telethon SR-TIGET Core Grant) to G.F. and by Pennsylvania Department of Health (Commonwealth Universal Research Enhancement - C.U.R.E. Program), Children Hospital of Philadelphia (CuRED Frontier Program) and National Institute of Diabetes and Digestive and Kidney Diseases Institute of the National Institutes of Health (R01 DK090554 and R01 DK095112) to S.R.

CONFLICT OF INTEREST
Antonella Nai received research funding from Celgene (BMS group). Stefano Rivella is a member of scientific advisory board of Ionis Pharmaceuticals, Meira GTx, Incyte, Vifor and Disc Medicine and owns stock options from Disc Medicine. Stefano Rivella has been or is consultant for Cambridge Healthcare Res, Celgene Corporation, Cationion, First Manhattan Co., FORMA Therapeutics, Ghost Tree Capital, Keros Therapeutics, Noble insight, Protagonist Therapeutics, Sanofi Aventis U.S., Slingshot Insight, Techtspertio and BVF Partners L.P., Rallybio, LLC, venBio Select LLC. The other authors declare no financial conflict-of-interest.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon request.

ORCID
Laura Silvestri https://orcid.org/0000-0002-8726-9808
Antonella Nai https://orcid.org/0000-0002-0739-5282

REFERENCES
1. Khondros E, Thom CS, D’Souza J, Weiss MJ. Integrated protein quality-control pathways regulate free alpha-globin in murine beta-thalassemia. Blood. 2012;119(22):5265-5275.
2. Chen JJ, Zhang S. Heme-regulated elf2alpha kinase in erythropoiesis and hemoglobinopathies. Blood. 2019;134(20):1697-1707.
3. Taher AT, Musallam KM, Cappellini MD. beta-Thalassemias. N Engl J Med. 2021;384(8):727-743.
4. Kautz L, Jung G, Valore EV, Rivella S, Nemeth E, Ganz T. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet. 2014;46(7):678-684.
5. Kautz L, Jung G, Du X, et al. Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model of beta-thalassemia. Blood. 2015;126(17):2031-2037.
6. Origa R, Galanello R, Ganz T, et al. Liver iron concentrations and urinary hepcidin in beta-thalassemia. Haematologica. 2007;92(5):583-588.
7. Nemeth E. Hepcidin in beta-thalassemia. Ann N Y Acad Sci. 2010;1202:31-35.
8. van Vuren AJ, Sharfo A, Grootendorst ST, et al. A comprehensive analysis of the erythropoietin-erythroferrone-hepcidin pathway in hereditary hemolytic anemias. Hema. 2021;5(9):e627.
9. Camaschella C, Nai A. Ineffective erythropoiesis and regulation of iron status in iron loading anemias. Br J Haematol. 2016;172(4):512-523.
10. Gupta R, Musallam KM, Taher AT, Rivella S. Ineffective erythropoiesis: anemia and iron overload. Hematol Oncol Clin North Am. 2018;32(2):213-221.
11. Rivella S. Iron metabolism under conditions of ineffective erythropoiesis in beta-thalassemia. Blood. 2019;133(1):51-58.
12. Viprakasit V, Ekwanthanakit S. Clinical classification, screening and diagnosis for thalassemia. Hematol Oncol Clin North Am. 2018;32(2):193-211.
13. Cappellini MD, Cohen A, Porter J, Taher AT, Viprakasit V. Guidelines for the Management of Transfusion Dependent Thalassemia (TDT). 3rd ed. Thalassaemia International Federation; 2014.
14. Cappellini MD, Marcon A, Fattizzo B, Motta I. Innovative treatments for rare anemias. Hemapheres. 2021;5(6):e576.
15. Angelucci E, Matthes-Martin S, Barocianci D, et al. Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel. Haematologica. 2014;99(5):811-820.
16. Caocci G, Orofino MG, Vacca A, et al. Long-term survival of beta thalassemia major patients treated with hematopoietic stem cell transplantation compared with survival with conventional treatment. Am J Hematol. 2017;92(12):1303-1310.
17. Mohamed SY. Thalassemia major: transplantation or transfusion and chelation. Hematol Oncol Stem Cell Ther. 2017;10(4):290-298.
18. Piga A, Perrotta S, Gamberini MR, et al. Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with beta-thalassemia. Blood. 2019;133(12):1279-1289.
19. Cappellini MD, Viprakasit V, Taher AT, et al. A phase 3 trial of Luspatercept in patients with transfusion-dependent beta-thalassemia. N Engl J Med. 2020;382(13):1219-1231.
20. Thompson AA, Walters MC, Kwiatkowski J, et al. Gene therapy in patients with transfusion-dependent beta-thalassemia. N Engl J Med. 2018;378(16):1479-1493.
21. Marktel S, Scaramuzza S, Cicalese MP, et al. Intrabone hematopoietic stem cell gene therapy for adult and pediatric patients affected by transfusion-dependent ss-thalassemia. Nat Med. 2019;25(2):234-241.
22. Locatelli F, Thompson AA, Kwiatkowski JL, et al. Betibegogene Autotemcel gene therapy for non-beta(0)/beta(0) genotype beta-thalassemia. N Engl J Med. 2022;386(5):415-427.
23. Magrin E, Semeraro M, Hebert N, et al. Long-term outcomes of lenti-viral gene therapy for the beta-hemoglobinopathies: the HGB-205 trial. Nat Med. 2022;28(1):81-88.
24. Musallam KM, Bou-Fakhredin R, Cappellini MD, Taher AT. 2021 update on clinical trials in beta-thalassemia. Am J Hematol. 2021;96(11):1518-1531.
25. Camaschella C, Roetta A, Cali A, et al. The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22. Nat Genet. 2000;25(1):14-15.
26. Rapisarda C, Puppi J, Hughes RD, et al. Transferrin receptor 2 is crucial for iron sensing in human hepatocytes. Am J Physiol Gastroint Liver Physiol. 2010;299(3):G778-G783.
27. Nemeth E, Roetta A, Garozzo G, Ganz T, Camaschella C. Hepcidin is decreased in TFR2 hemochromatosis. Blood. 2005;105(4):1803-1806.
28. Kawabata H, Fleming RE, Gui D, et al. Expression of hepcidin is down-regulated in TFR2 mutant mice manifesting a phenotype of hereditary hemochromatosis. Blood. 2005;105(1):376-381.
29. Wallace DF, Summerville L, Subramanian VN. Targeted disruption of the hepatic transferrin receptor 2 gene in mice leads to iron overload. Gastroenterology. 2007;132(1):301-310.
30. Gao J, Chen J, Kramer M, Tsukamoto H, Zhang AS, Enns CA. Interaction of the hereditary hemochromatosis protein HFE with transferrin receptor 2 is required for transferrin-induced hepcidin expression. Cell Metab. 2009;9(3):217-227.

31. Corradini E, Rozier M, Meynard D, et al. Iron regulation of hepcidin despite attenuated Smad1,5,8 signaling in mice without transferrin receptor 2 or Hfe. Gastroenterology. 2011;141(5):1907-1914.

32. D’Alessio F, Hentze MW, Muckenthaler MU. The hemochromatosis proteins HFE, TFR2, and HJV form a membrane-associated protein complex for hepcidin regulation. J Hepatol. 2012;57(5):1052-1060.

33. Forejtnikova H, Vieillevoye M, Zermati Y, et al. Transferrin receptor 2 protein levels by transferrin. Blood. 2004;104(3):4287-4293.

34. Robb A, Wessling-Resnick M. Regulation of transferrin receptor 2 protein stability. Blood. 2004;104(13):2492-2499.

35. Pagani A, Vieillevoye M, Nai A, et al. The second transferrin receptor regulates red blood cell production in mice. Blood. 2015;125(7):1170-1179.

36. Johnson MB, Enns CA. Diferred transferrin regulates transferrin receptor 2 protein stability. Blood. 2004;104(13):4287-4293.

37. Robb A, Wessling-Resnick M. Regulation of transferrin receptor 2 protein levels by transferrin. Blood. 2004;104(13):2492-2499.

38. Johnson MB, Chen J, Murchison N, Green FA, Enns CA. Transferrin receptor 2 is required for transferrin-induced hepcidin expression. Blood. 2010;116(24):5357-5367.

39. Nai A, Lidonnici MR, Rausa M, et al. The second transferrin receptor regulates red blood cell production in mice. Blood. 2015;125(7):1170-1179.

40. Johnson MB, Enns CA. Diferred transferrin regulates transferrin receptor 2 protein stability. Blood. 2004;104(13):4287-4293.

41. Robb A, Wessling-Resnick M. Regulation of transferrin receptor 2 protein levels by transferrin. Blood. 2004;104(13):2492-2499.

42. Pagani A, Vieillevoye M, Nai A, et al. Regulation of cell surface transferrin receptor-2 by iron-dependent cleavage and release of a soluble form. Haematologica. 2015;100(4):458-465.

43. Johnson MB, Chen J, Murchison N, Green FA, Enns CA. Transferrin receptor 2: evidence for ligand-induced stabilization and redirection to a recycling pathway. Mol Biol Cell. 2007;18(3):743-754.

44. Artuso I, Lidonnici MR, Altamara S, et al. Transferrin receptor 2 is a potential novel therapeutic target for beta-thalassemia: evidence from a murine model. Blood. 2018;132(21):2286-2297.

45. Casu C, Pettinato M, Liu A, et al. Correcting beta-thalassemia by combined therapies that restrict iron and modulate erythropoietin activity. Blood. 2020;136(17):1968-1979.

46. Schmidt PJ, Fitzgerald K, Butter JS, Fleming MD. Global loss of Tfr2 with concomitant induced iron deficiency greatly ameliorates the phenotype of a murine thalassemia intermedia model. Am J Hematol. 2021;96(2):251-257.

47. Nai A, Pagani A, Mandelli G, et al. Deletion of TMPRSS6 attenuates the phenotype in a mouse model of beta-thalassemia. Blood. 2012;119(21):5021-5029.

48. Guo S, Casu C, Gardenghi S, et al. Reducing TMPRSS6 ameliorates hemochromatosis and beta-thalassemia in mice. J Clin Invest. 2013;123(4):1531-1541.

49. Casu C, Chessa R, Liu A, et al. Minihemepins improve ineffective erythropoiesis and splenomegaly in a new mouse model of adult beta-thalassemia major. Haematologica. 2020;105(7):1835-1844.

50. Skow LC, Burkhart BA, Johnson FM, et al. A mouse model for beta-thalassemia. Cell. 1983;34(3):1043-1052.

51. Silva M, Benito A, Sanz C, et al. Erythropoietin can induce the expression of bcl-x(L) through Stats in erythropoietin-dependent progenitor cell lines. J Biol Chem. 1999;274(32):22165-22169.

52. Chimba T, Ikawa Y, Todokoro K. GATA-1 transactivates erythropoietin receptor gene, and erythropoietin receptor-mediated signals enhance GATA-1 gene expression. Nucleic Acids Res. 1991;19(14):3843-3848.

53. Deindl P, Klar M, Drews D, et al. Mice over-expressing human erythropoietin indicate that erythropoietin enhances expression of its receptor via up-regulated Gata1 and Tal1. Haematologica. 2014;99(10):e205-e207.

54. Mettananda S. Genetic and epigenetic therapies for beta-Thalassemia by altering the expression of alpha-globin gene. Front Genome Ed. 2021;3:752278.

55. Hashemi Z, Ebrahimzadeh MA. Hemoglobin F (HbF) inducers; history, structure and efficacies. Min Rev Med Chem. 2022;22(1):52-68.

56. Feng L, Gell DA, Zhou S, et al. Molecular mechanism of AHSP-mediated stabilization of alpha-hemoglobin. Cell. 2004;119(5):629-640.

57. Kong Y, Zhou S, Kihm AJ, et al. Loss of alpha-hemoglobin-stabilizing protein impairs erythropoiesis and exacerbates beta-thalassemia. J Clin Invest. 2004;114(10):1457-1466.

58. Marinii MG, Porcu L, Asunis I, et al. Regulation of the human HBA genes by KLF4 in erythroid cell lines. Br J Haematol. 2010;149(5):748-758.

59. Sangwung P, Zhou G, Lu Y, et al. Regulation of endothelial hemoglobin alpha expression by Kruppel-like factors. Vasc Med. 2017;22(5):363-369.

60. Kalra IS, Alam MM, Choudhary PK, Pace BS. Kruppel-like factor 4 activates HBG gene expression in primary erythroid cells. Br J Haematol. 2011;154(2):248-259.

61. Hirota M, Itagaki M, Itagaki H, Alba S. Quantitative measurement of spliced XBP1 mRNA as an indicator of endoplasmic reticulum stress. J Toxicol Sci. 2006;31(2):149-156.

62. Koutsoumi Y, Segal M, Normington K, Gething MJ, Sambrook J. The presence of malfolded proteins in the endoplasmic reticulum signals the induction of glucose-regulated proteins. Nature. 1988;332(6163):462-464.

63. Novoa I, Zeng H, Harding HP, Ron D. Feedback inhibition of the unfolded protein response by GADD34-mediated dephosphorylation of eIF2alpha. J Cell Biol. 2001;153(5):1011-1022.

64. Harding HP, Zhang Y, Zeng H, et al. An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Mol Cell. 2003;11(3):619-633.

65. Wydadomari S, Mori M. Roles of CHOP/GADD153 in endoplasmic reticulum stress. Cell Death Differ. 2004;11(4):381-389.

66. Nishitoh H. CHOP is a multifunctional transcription factor in the ER stress response. J Biochem. 2012;151(3):217-219.

67. Cavall I, Ricketts C, Jacobs A, Letsky E. Erythropoiesis and the effect of transfection in homoygous beta-thalasemia. N Engl J Med. 1978;279(14):776-778.

68. Pasricha SR, Chowdhary PK, Bowden DK, Anderson GJ. Transfusion suppresses erythropoiesis and increases hepcidin in adult patients with beta-thalassemia major: a longitudinal study. Blood. 2013;122(1):124-133.

69. Chauhan W, Shoaib S, Fatma R, Zaka-Ur-Rab Z, Afzal M. Beta-thalassemia, and the advent of new interventions beyond transfusion and iron chelation. Br J Clin Pharmacol. 2022;88:3610-3626.

70. Barone MV, Crozat A, Tabae D, Philippsin L, Ron D. CHOP (GADD153) and its oncogenic variant, TLS-CHOP, have opposing effects on the induction of G1/S arrest. Genes Dev. 1994;8(4):453-464.

71. Cui K, Coutts M, Stahl J, Strykowski AJ. Novel interaction between the transcription factor CHOP (GADD153) and the ribosomal protein FTE/S3a modulates erythropoiesis. J Biol Chem. 2000;275(11):7591-7596.
72. Zhou AX, Wang X, Lin CS, et al. C/EBP-homologous protein (CHOP) in vascular smooth muscle cells regulates their proliferation in aortic explants and atherosclerotic lesions. *Circ Res*. 2015;116(11):1736-1743.

73. Sazani P, Gemignani F, Kang SH, et al. Systemically delivered antisense oligomers upregulate gene expression in mouse tissues. *Nat Biotechnol*. 2002;20(12):1228-1233.

74. Halloy F, Iyer PS, Cwiek P, et al. Delivery of oligonucleotides to bone marrow to modulate ferrochelatase splicing in a mouse model of erythropoietic protoporphyria. *Nucleic Acids Res*. 2020;48(9):4658-4671.

75. Cheng H, Chawla A, Yang Y, et al. Development of nanomaterials for bone-targeted drug delivery. *Drug Discov Today*. 2017;22(9):1336-1350.

76. Mu CF, Shen J, Liang J, et al. Targeted drug delivery for tumor therapy inside the bone marrow. *Biomaterials*. 2018;155:191-202.

**SUPPORTING INFORMATION**

Additional supporting information can be found online in the Supporting Information section at the end of this article.

---

**How to cite this article:** Di Modica SM, Tanzi E, Olivari V, et al. *Transferrin receptor 2 (Tfr2) genetic deletion makes transfusion-independent a murine model of transfusion-dependent β-thalassemia*. *Am J Hematol*. 2022;97(10):1324-1336. doi:10.1002/ajh.26673